Drug Approval | January 13, 2022
South Korea approves Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The last date to apply for this program is 18th January 2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
This test analyses samples in VTM directly without the need for RNA extraction step
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
The stability is led by healthy demand in the domestic and emerging markets
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
This surpasses the number of approvals supported in 2020
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Ind-Ra expects revenue growth of over 12% in 2022.
Subscribe To Our Newsletter & Stay Updated
